Hedge Fund Manager Ubben Commits To Valeant Relationship

Mark Melin

Published onSeptember 25, 2014

Updated on May 13, 2021

Jeffrey Ubben and his Hedge fund ValueAct are more strongly committed to their second largest holding, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), than ever before.

Ubben made negative comments about Valeant, Allergan deal

After ValueAct’s representative on the Valeant board, Mason Morfit, stepped down from his board seat in May to devote time to ValueAct’s largest holding, Microsoft Corporation (NASDAQ:MSFT), and Ubben subsequently made negative comments about Valeant's acquisition about Allergan, Inc. (NYSE:AGN), whispers wondered if the hedge fund was still committed to its relationship with the medical roll-up firm.

That changes with today's announcement.

"They're basically saying: 'We're back...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Hedge Fund Manager Ubben Commits To Valeant Relationship

Ubben made negative comments about Valeant, Allergan deal

Login required to continue reading.

Get Your Business News